May 14, 2019 / 04:20PM GMT
Ying Huang - BofA Merrill Lynch, Research Division - Director in Equity Research
All right. Great. So let's get started. My name is Ying Huang, and I'm a senior analyst covering large cap healthcare here at BofA Merrill Lynch. Welcome to the first day of our conference in Las Vegas. Our next presenting company is Moderna Therapeutics. Moderna actually went public recently, and it's actually one of the largest IPOs in history of [tal tech]. So we're pleased to have Lorence Kim, the Chief Financial Officer of Moderna; and also Dr. Tal Zaks, the Chief Medical Officer from Moderna with us.
Questions and Answers:
Ying Huang - BofA Merrill Lynch, Research Division - Director in Equity ResearchSo with that, let me just kick off maybe by asking Lorence a high-level question. That is, there are many different approaches for RNA therapeutics in the market and also under -- I mean in the stock market, not in commercial market yet. So can you talk about what's the unique approach about the messenger RNA Moderna is pioneering in the development field? And how do you
Trustpilot
